Skip to content

Significance of serum hCG rise on the 4th day after single MX treatment in patients with ectopic pregnancy

Significance of serum hCG rise on the 4th day after single MX treatment in patients with ectopic pregnancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030658
Enrollment
Unknown
Registered
2020-03-08
Start date
2020-03-09
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic Pregnancy

Interventions

Two groups:The second MTX treatment on day 4 after one dose MTX theropy

Sponsors

Shanghai First Maternity and Infant Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. EP patients with definite diagnosis and menopause time no more than 60 days; 2. Patients without obvious abnormality in blood routine examination, with higher serum beta hCG concentration and without acute abdominal symptoms on day 4; 3. Patients whose transvaginal ultrasound showed no abnormal uterine size; 4. Patients who are generally in good condition without hepatorenal disease or other serious systemic diseases; 5. Patients have a strong desire for childbearing and good compliance; 6. All patients voluntarily participate in the study and sign the treatment consent.

Exclusion criteria

Exclusion criteria: 1. The patients whose blood beta hCG decreased from the initial concentration on the 4th day; 2. With severe cardiopulmonary hepatorenal; 3. With severe blood diseases; 4. Initial concentration over 2000 mIU / ml; 5. Patients with general instability and internal bleeding; 6. With the diameter of pregnancy mass is more than 4cm; 7. Patients with gestational sac visible in the mass of gestational sac; 8. Cases that do not meet the inclusion criteria or the case report records are not standardized; 9. Cases launched due to adverse reactions or poor efficacy; 10. Cases with poor compliance and lack of follow-up.

Design outcomes

Primary

MeasureTime frame
serum beta-hCG;serum;

Countries

China

Contacts

Public ContactShuangdi Li

Shanghai First Maternity and Infant Hospital

lishuangdi21@126.com+86 15921664530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026